EVolution Therapeutics has achieved another milestone by securing additional grant funding of £238,000, to work in collaboration with world leading biomaterials expert, Professor Paul Topham. This funding aims to bolster the development of polymer hydrogel delivery systems for topical application of EVolution Therapeutics EV-based therapy.
Professor Topham, Head of Chemical Engineering and Applied Chemistry (CEAC) at Aston University and Director of the Aston Institute of Materials Research (AIMR), brings a wealth of expertise to the table. His research focus on well-defined polymer systems, including “smart” polymers and biocompatible materials, aligns perfectly with EVolution Therapeutics’ mission.
This grant will specifically support the development and production of EV-loaded polymer hydrogels. These hydrogels hold immense promise as potential wound dressings in EVolution Therapeutics’ pursuit of innovative therapeutics for chronic wounds.
By developing a novel advanced biological therapy, we aim to not only mitigate the cost burden to global healthcare systems worldwide, but also enhance the quality of life for individuals affected by these onerous conditions. Our innovative approach holds the potential to revolutionise wound care practices, offering hope for improved outcomes and reduced morbidity and mortality rates among patients globally.